|
|
|
|
| LEADER |
02910nmm a2200361 u 4500 |
| 001 |
EB001082175 |
| 003 |
EBX01000000000000000841582 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
151019 ||| eng |
| 100 |
1 |
|
|a Masters, Colin L.
|
| 245 |
0 |
0 |
|a Abeta toxicity
|h Elektronische Ressource
|b Part 1
|c Colin L. Masters
|
| 246 |
3 |
1 |
|a Aβ toxicity, Part I
|
| 246 |
3 |
1 |
|a Abeta toxicity, Part I
|
| 260 |
|
|
|a London
|b Henry Stewart Talks
|c 2011, 2011
|
| 300 |
|
|
|a 1 online resource (1 streaming video file (54 min.)
|b color, sound)
|
| 505 |
0 |
|
|a The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. PBT2 -- Alzheimer's disease Abeta-directed therapeutics in clinical development: drugs and biologics -- Phase II results of Abeta targeting AD modifying drugs
|
| 653 |
|
|
|a Alzheimer's disease / Chemotherapy
|
| 653 |
|
|
|a Alzheimer's disease / Pathophysiology
|
| 653 |
|
|
|a Alzheimer Disease / therapy
|
| 653 |
|
|
|a Amyloid beta-Peptides / toxicity
|
| 653 |
|
|
|a Alzheimer's disease / Treatment
|
| 653 |
|
|
|a Alzheimer Disease / drug therapy
|
| 653 |
|
|
|a Amyloid beta-protein
|
| 653 |
|
|
|a Alzheimer Disease / physiopathology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b HST
|a Henry Stewart Talks
|
| 490 |
0 |
|
|a Alzheimer's disease : neurobiology, pathology and treatment
|
| 500 |
|
|
|a Animated audio-visual presentation with synchronized narration. - Title from publisher's website (viewed January 2012). - Mode of access: World Wide Web. - System requirements: Browser compatibility: updated Mozilla Firefox, Google Chrome, Safari or Internet Explorer 8+. Browser settings: enable JavaScript, enable cookies from the Henry Stewart Talks site. Required Desktop Browser plugins & viewers: Updated Adobe Flash Player & Adobe Acrobat Reader. Mobile device & operating system versions: Android v4.0+, iPhone 4+ (iOS v6.x+), iPad 2+ (iOS v6.x+), BlackBerry OS v7.0+, Windows Phone v6.5.1+
|
| 856 |
4 |
0 |
|u https://hstalks.com/bs/2131
|x Verlag
|z Streaming video file
|
| 856 |
4 |
2 |
|u https://hstalks.com/bs/p/529
|3 Series (Alzheimer disease)
|
| 856 |
4 |
2 |
|u https://hstalks.com/bs/p/684
|3 Series (Drug discovery and development in the neurosciences)
|
| 082 |
0 |
|
|a 570
|